GILD: Gilead Sciences Inc. Stocks News on December 20, 2024

GILD

Zacks

19 hours ago

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

GILD

MT Newswires

a day ago

Assembly Biosciences Says It Will Receive $30.1 Million Funding From Gilead Sciences

GILD

Zacks

2 days ago

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

GILD

Zacks

2 days ago

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

Gilead, Terray Therapeutics announce research collaboration

GILD

TipRanks

2 days ago

Gilead, Terray Therapeutics announce research collaboration

Gilead and Terray link to develop small-molecule therapies

GILD

Pharmaceutical Technology

2 days ago

Gilead and Terray link to develop small-molecule therapies

GILD

MT Newswires

3 days ago

Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

GILD

Business Wire

3 days ago

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

GILD

MT Newswires

3 days ago

Gilead Sciences, Terray Therapeutics to Collaborate on Novel Small Molecule Therapies

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

GILD

Business Wire

3 days ago

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

GILD

Zacks

4 days ago

GILD Obtains Positive CHMP Opinion for Liver Disease Drug

GILD

Zacks

4 days ago

Gilead (GILD) Upgraded to Buy: Here's Why

GILD

Zacks

7 days ago

Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

GILD

Benzinga

7 days ago

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

GILD

MT Newswires

7 days ago

Gilead Sciences Says EU Panel Recommends Seladelpar for Primary Biliary Cholangitis

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

GILD

Business Wire

7 days ago

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

GILD

Reuters

8 days ago

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

GILD

MT Newswires

8 days ago

Gilead Sciences Names Dietmar Berger as Chief Medical Officer

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

GILD

Business Wire

8 days ago

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

GILD

Benzinga

8 days ago

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

GILD

Zacks

8 days ago

Is Gilead Sciences (GILD) Stock Undervalued Right Now?

GILD

Zacks

8 days ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers

GILD

Benzinga

8 days ago

Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers

GILD

MT Newswires

9 days ago

Leerink Partners Adjusts Gilead Sciences Price Target to $99 From $96, Maintains Outperform Rating

GILD

MT Newswires

10 days ago

Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says

GILD

MT Newswires

10 days ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating

GILD

MT Newswires

10 days ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Keeps Outperform Rating

GILD

Zacks

10 days ago

The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group

GILD

MT Newswires

11 days ago

Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy

$Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024$

GILD

Business Wire

11 days ago

Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

GILD

Business Wire

11 days ago

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

GILD

Investor's Business Daily

11 days ago

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences

GILD

Zacks

11 days ago

Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences

$Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH$

GILD

Business Wire

12 days ago

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.

GILD

Barrons.com

15 days ago

Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.

Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC

GILD

Zacks

16 days ago

Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC

GILD

MT Newswires

16 days ago

HSBC Adjusts Price Target on Gilead Sciences to $82 From $69

GILD

MT Newswires

17 days ago

Gilead Sciences Insider Sold Shares Worth $23,065,271, According to a Recent SEC Filing

PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy

GILD

Zacks

17 days ago

PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy

GILD

Zacks

17 days ago

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

GILD

MT Newswires

17 days ago

Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

GILD

Business Wire

17 days ago

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

GILD

Morningstar Research

18 days ago

Analyst Report: Gilead Sciences, Inc.

GILD

MT Newswires

18 days ago

Jefferies Raises Price Target on Gilead Sciences to $115 From $105

Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

GILD

Zacks

21 days ago

Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

GILD

Zacks

21 days ago

GILD vs. VRTX: Which Stock Should Value Investors Buy Now?

Gilead announces PURPOSE 2 trial data published in NEJM

GILD

TipRanks

22 days ago

Gilead announces PURPOSE 2 trial data published in NEJM

GILD

Zacks

22 days ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial

GILD

Clinical Trials Arena

22 days ago

Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results

GILD

Business Wire

23 days ago

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech

GILD

Pharmaceutical Technology

24 days ago

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech

Exploring Three High Growth Tech Stocks In The United States

GILD

Simply Wall St.

25 days ago

Exploring Three High Growth Tech Stocks In The United States

GILD

Argus Research

25 days ago

Weekly Stock List

GILD

MT Newswires

a month ago

UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

GILD

TipRanks

a month ago

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

GILD

MT Newswires

a month ago

Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90

GILD

Argus Research

a month ago

Analyst Report: Gilead Sciences, Inc.

GILD

Argus Research

a month ago

Market Digest: ADTN, EQR, GILD, NFG, PRU, MSCI

GILD

MT Newswires

a month ago

Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73

GILD

MT Newswires

a month ago

RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81

Gilead’s Livdelzi shows promise in PBC clinical trial

GILD

Clinical Trials Arena

a month ago

Gilead’s Livdelzi shows promise in PBC clinical trial

GILD

Morningstar Research

a month ago

Analyst Report: Gilead Sciences, Inc.

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

GILD

Benzinga

a month ago

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

GILD

MT Newswires

a month ago

Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response

GILD

Business Wire

a month ago

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

GILD

MT Newswires

a month ago

Wolfe Research Initiates Gilead Sciences at Outperform With $110 Price Target

GILD

Investing.com

a month ago

Citi initiates coverage on 5 new biotech stocks

GILD

Zacks

a month ago

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

GILD

Zacks

a month ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

GILD

MT Newswires

a month ago

Gilead Sciences Prices $3.5 Billion Senior Notes Offering

Gilead Prices $3.5 Billion of Senior Unsecured Notes

GILD

Business Wire

a month ago

Gilead Prices $3.5 Billion of Senior Unsecured Notes

GILD

Simply Wall St.

a month ago

Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear

GILD

MT Newswires

a month ago

Gilead Sciences Says Investigational HIV Prevention Drug Showed High Infection Reduction

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

GILD

Business Wire

a month ago

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

GILD

GuruFocus.com

a month ago

Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight

GILD

Zacks

a month ago

GILD or VRTX: Which Is the Better Value Stock Right Now?

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

GILD

Business Wire

a month ago

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

3 Spectacular High-Yield Dividend Stocks to Buy in November

GILD

Motley Fool

a month ago

3 Spectacular High-Yield Dividend Stocks to Buy in November

Gilead Sciences to Present at Upcoming Investor Engagements

GILD

Business Wire

a month ago

Gilead Sciences to Present at Upcoming Investor Engagements

GILD

Morningstar Research

a month ago

Analyst Report: Gilead Sciences, Inc.

GILD

MT Newswires

a month ago

Maxim Downgrades Gilead Sciences to Hold From Buy

Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

GILD

Simply Wall St.

a month ago

Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

GILD

MT Newswires

a month ago

Truist Securities Raises Price Target on Gilead Sciences to $97 From $83, Maintains Hold Rating

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise

GILD

Investor's Business Daily

a month ago

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

GILD

Benzinga

a month ago

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

Gilead increases 2024 outlook, expects new drug filing by end of year

GILD

Yahoo Finance

a month ago

Gilead increases 2024 outlook, expects new drug filing by end of year

GILD

MT Newswires

a month ago

Raymond James Adjusts Gilead Sciences Price Target to $103 From $95, Maintains Outperform Rating

Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook

GILD

Zacks

a month ago

Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

GILD

Business Wire

a month ago

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

GILD

MT Newswires

a month ago

JPMorgan Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating

GILD

MT Newswires

a month ago

Barclays Adjusts Price Target on Gilead Sciences to $95 From $84, Maintains Equalweight Rating

GILD

MT Newswires

a month ago

TD Cowen Adjusts Price Target on Gilead Sciences to $95 From $85, Maintains Buy Rating

GILD

MT Newswires

a month ago

BMO Capital Adjusts Price Target on Gilead Sciences to $102 From $94, Maintains Outperform Rating

GILD

MT Newswires

a month ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Outperform Rating

GILD

MT Newswires

a month ago

Piper Sandler Adjusts Price Target on Gilead Sciences to $105 From $95, Maintains Overweight Rating

GILD

MT Newswires

a month ago

Wells Fargo Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Overweight Rating

GILD

GuruFocus.com

a month ago

Gilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales ...

GILD

Motley Fool

a month ago

Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript

GILD

Zacks

a month ago

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say

GILD

Zacks

a month ago

Latest Gilead Sciences Inc. (GILD) News on December 20, 2024

Share on Social Networks: